Evidence map›Paper›PMID 25370301›Full record

ArticlePathology oncology research : POR2015

Immunophenotype and human papillomavirus status of serous adenocarcinoma of the uterine cervix.

Shinichi Togami, Yuko Sasajima, Takahiro Kasamatsu, Rie Oda-Otomo, Satoshi Okada, Mitsuya Ishikawa, Shun-ichi Ikeda, Tomoyasu Kato, Hitoshi Tsuda

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Pathology oncology research : POR, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 23 citations in OpenAlex.

  1. Cervical carcinomas with serous-like papillary and micropapillary components: illustrating the heterogeneity of primary cervical carcinomas.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021
    Article
  2. Review
  3. Review
  4. Article
  5. The association between expression of p53 and aggressiveness of serous adenocarcinoma of the uterine cervix.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2020
    Article
  6. Recent advances in invasive adenocarcinoma of the cervix.Virchows Archiv : an international journal of pathology · 2019
    Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Shinichi TogamiDepartment of Gynecology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan, togami@m3.kufm.kagoshima-u.ac.jp.
Yuko Sasajima
Takahiro Kasamatsu
Rie Oda-Otomo
Satoshi Okada
Mitsuya Ishikawa
Shun-ichi Ikeda
Tomoyasu Kato
Hitoshi Tsuda
National Cancer Center Hospital East · JPNational Cancer Center · USTeikyo University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Serous adenocarcinoma of the cervix (SACC) is a very rare tumor. Our study aimed to characterize the immune profile and human papillomavirus (HPV) status of SACC, in comparison with other serous adenocarcinomas arising in the female genital tract. The pathological specimens obtained from 81 patients with serous carcinoma of the uterine cervix (n = 12), 29 endometrium, 20 ovary and 20 patients with mucinous carcinoma of the uterine cervix were reviewed. We assessed the expression of WT-1, p53, p16, HER2, CEA, and CA125 by immunohistochemistry and HPV DNA by PCR in 12 SACC samples. Their immune profile was compared with that of uterine papillary serous carcinoma (UPSC), ovarian serous adenocarcinoma (OSA), and mucinous endocervical adenocarcinoma (MEA). WT-1 and HER2 were expressed in very few SACC samples (0 and 0%, respectively), but p16, CA125, CEA and p53 were present in 100, 92, 58 and 50%, respectively. The difference in WT-1 expression between SACC and UPSC, MEA is not significant, but SACC differ significantly from OSA (p < 0.01). HPV DNA (type 16 or 18) was detected in 4 of the 12 SACC. The immunophenotype of SACC was similar to UPSC, whereas the frequency of expression of WT-1 was significantly lower in SACC than OSA. It appeared that p53 expression was associated with worse clinical outcome in patients with SACC, and that HPV infection was related to its occurrence.

Indexed as

ImmunophenotypingPapillomaviridaeAdenocarcinomaCA-125 AntigenComorbidityCyclin-Dependent Kinase Inhibitor p16Endometrial NeoplasmsFemaleHumansImmunohistochemistryMembrane ProteinsNeoplasm ProteinsNeoplasms, Cystic, Mucinous, and SerousOvarian NeoplasmsPapillomavirus InfectionsRetrospective StudiesCA-125 AntigenCDKN2A protein, humanCyclin-Dependent Kinase Inhibitor p16Membrane ProteinsMUC16 protein, humanNeoplasm ProteinsTumor Suppressor Protein p53

Identifiers

PMID25370301
OpenAlexW2156021326

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.